Cargando…

Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience

Sodium-glucose cotransporter 2 (SGLT2) inhibitors include a relatively new class of glucose-lowering drugs that reduce plasma glucose concentrations by inhibiting proximal tubular reabsorption of glucose in the kidney, while increasing its excretion in urine. Recent large randomised controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwart, K., Velthuis, S., Polyukhovych, Y. V., Mosterd, A., Smidt, L., Serné, E. H., van Raalte, D. H., Elders, P. J. M., Handoko, M. L., Oldenburg-Ligtenberg, P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455761/ https://www.ncbi.nlm.nih.gov/pubmed/34132981 http://dx.doi.org/10.1007/s12471-021-01580-9

Ejemplares similares

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
por: van Raalte, Daniël H, et al.
Publicado: (2020)

Italian Association of Hospital Cardiologists practical guidance for sodium–glucose cotransporter 2 inhibitors use in patients with heart failure
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Early career perspectives of young Dutch cardiologists
por: Vorselaars, V. M. M., et al.
Publicado: (2021)

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
por: Adhikari, Rishav, et al.
Publicado: (2022)

Problems on the labour market for young Dutch cardiologists
por: Michels, M., et al.
Publicado: (2021)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

What do cardiologists know about the effects of cardiovascular agents on sexual function? A survey among Dutch cardiologists. Part I
por: Nicolai, M. P. J., et al.
Publicado: (2013)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Current practice of Dutch cardiologists in detecting and diagnosing atrial fibrillation: results of an online case vignette study
por: Verbiest-van Gurp, N., et al.
Publicado: (2017)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
por: Tharmaraja, Thahesh, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas
por: Kepe, Vladimir, et al.
Publicado: (2018)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
por: Tahrani, Abd A., et al.
Publicado: (2011)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_49ft00dj3in931qa37bvrdshus